Emphysema destroys the tiny air sacs in your lungs, and once those structures are gone, no existing treatment can grow them back. The damage is permanent in a strict anatomical sense: the walls between air sacs break down, merging small compartments into larger, less efficient ones that cannot exchange oxygen the way healthy tissue does. But “irreversible structural damage” and “nothing you can do” are very different statements. Slowing the disease, reclaiming some lost lung function, and dramatically improving daily life are all realistic goals, and some experimental approaches hint at genuine tissue regeneration down the road.
What Emphysema Actually Destroys
Your lungs contain roughly 300 million alveoli, grape-like sacs where oxygen passes into the blood and carbon dioxide passes out. In emphysema, the walls of these sacs degrade and collapse into one another. The result is fewer, larger air spaces with less total surface area for gas exchange. You also lose elastic recoil, meaning your lungs cannot spring back after each breath the way they should. That traps stale air inside the chest, a problem called hyperinflation, which makes every breath feel like you are trying to exhale through a pinched straw.
This process involves a cascade of enzymes, particularly elastases and metalloproteinases, that chew through the structural proteins holding alveolar walls together. The leading explanation for why this happens, proposed almost 50 years ago, centers on an imbalance between those destructive enzymes and the proteins meant to keep them in check.
Research on lung tissue from people at different stages of disease has shown that the damage starts earlier than most people realize. The narrowing and loss of the smallest airways, called terminal bronchioles, actually precedes the visible destruction of air sacs.
Why Quitting Smoking Is the Single Most Powerful Intervention
If you smoke and have early or moderate emphysema, quitting will not undo the damage that already exists, but it changes the trajectory of the disease more than any medication currently available. The landmark Lung Health Study followed people with mild-to-moderate COPD and found that those who quit smoking experienced an average improvement of about 47 milliliters in their lung capacity during the first year after quitting, while those who kept smoking lost about 32 milliliters over the same period.
That initial bump matters, but the long-term trend matters more. After that first-year improvement, lung function still declines with age in former smokers, just as it does in everyone. The difference is the speed of that decline. Sustained quitters lost lung function at roughly half the rate of continuing smokers, a pace comparable to people who had never smoked at all.
Other research has confirmed this pattern. In people with moderate COPD, smoking cessation cut the accelerated rate of lung function decline by about half.
Treatments That Improve How You Feel Without Reversing the Damage
Because the structural loss in emphysema is irreversible with current medicine, most treatments focus on managing the consequences of that loss. The goals are reducing breathlessness, improving exercise tolerance, and preventing flare-ups that accelerate decline.
- Bronchodilators: Long-acting inhaled medications relax the muscles around your airways, improving airflow and helping your lungs empty more completely. This directly reduces hyperinflation, which is often the main driver of the feeling that you cannot catch your breath.
- Pulmonary rehabilitation: Structured exercise programs teach your body to use oxygen more efficiently. By lowering the breathing rate during exertion and reducing how hard your respiratory muscles have to work, exercise training can meaningfully improve what you are able to do each day.
- Combination approaches: Bronchodilators and exercise together tend to work better than either alone, because the medication reduces the mechanical limitation while the training improves how your muscles perform within that limitation.
For people with very severe COPD, even high-intensity exercise can feel impossible. Research into using noninvasive ventilatory support during exercise has shown that unloading the respiratory muscles may redirect blood flow toward the legs and arms, improving oxygen delivery to the muscles doing the actual work. This is not a cure, but it opens a window for training that would otherwise be too exhausting to sustain.
Bronchoscopic Lung Volume Reduction
When emphysema is advanced and concentrated in certain areas of the lung, a procedure called bronchoscopic lung volume reduction can produce real, measurable improvements. Small one-way valves are placed inside the airways leading to the most damaged lobe. These valves let air and mucus escape but prevent new air from entering, causing the destroyed section to gradually deflate. Once that over-inflated, useless tissue shrinks, healthier parts of the lung have room to expand and work better.
A randomized trial of endobronchial valves in people with advanced heterogeneous emphysema found that treated patients gained about a 4.3 percent increase in lung function at six months, while the control group lost about 2.5 percent, for a net difference of nearly 7 percent. Improvements in exercise capacity and symptoms followed a similar pattern. The catch is that valve treatment also came with higher rates of COPD flare-ups, pneumonia, and coughing up blood after the procedure.
Not everyone qualifies. The best candidates have severe hyperinflation, a clearly identifiable target lobe where the damage is concentrated, and no significant air leakage between lobes (a phenomenon called collateral ventilation that would let air sneak around the valves). For people who do meet the criteria, valve therapy is now a guideline-recommended option.
Alpha-1 Antitrypsin Deficiency and Augmentation Therapy
Most emphysema is caused by smoking, but a genetic condition called alpha-1 antitrypsin deficiency can lead to emphysema even in people who have never smoked. Alpha-1 antitrypsin is a protein that normally protects your lungs from the enzymes that break down tissue. People who produce too little of it are left vulnerable to lung damage from ordinary inflammatory processes.
The specific treatment for this condition is augmentation therapy: regular intravenous infusions of the missing protein, collected from donor blood. This raises the level of protective protein in the lungs, restores the balance between destructive enzymes and their inhibitors, and tamps down inflammation. Augmentation therapy does not reverse existing damage, but it slows the rate at which lung tissue is lost over time, which for a young person diagnosed early can mean decades of better lung function than they would have had without treatment.
Biologics for COPD With Type 2 Inflammation
A newer frontier in COPD treatment borrows from asthma research. Some people with COPD have elevated levels of a specific type of immune response, called type 2 inflammation, marked by high counts of certain white blood cells called eosinophils. For this subgroup, biologic drugs originally developed for severe asthma are showing promise.
Dupilumab, an injectable antibody that blocks two key inflammatory signals, was tested in two large trials of people with moderate-to-severe COPD and signs of type 2 inflammation. In the first trial, called BOREAS, it reduced moderate or severe flare-ups by 30 percent, improved lung function by about 83 milliliters, and improved quality-of-life scores compared to placebo. The second trial, NOTUS, confirmed the pattern with a 34 percent reduction in flare-ups and a 62 milliliter improvement in lung function.
These are meaningful results, but they are notably more modest than what dupilumab achieves in asthma, where flare-ups drop by about half. And this approach only helps the subset of COPD patients with the right inflammatory profile. Still, for people who keep having flare-ups despite maximal inhaler therapy, biologics represent something genuinely new.
Can Stem Cells or Retinoids Actually Regrow Lung Tissue?
This is the question that generates the most hope and the most misleading clinic advertisements. The honest answer is that regenerative approaches have shown tantalizing results in animals but have not yet delivered structural repair in humans.
In rat models of emphysema, retinoic acid, the active form of vitamin A, has been shown to completely restore lung architecture and surface area to normal. The idea is that retinoic acid reactivates the same gene programs that built the alveoli during fetal and newborn development, essentially tricking adult lung tissue into growing new air sacs. This was a striking finding, but translating it to human lungs, which are far larger and structurally different from rat lungs, has proven difficult. Clinical trials in people have not reproduced the dramatic regeneration seen in rodents.
Stem cell therapy has followed a similar arc. Early-phase clinical trials using mesenchymal stem cells in people with COPD have mostly demonstrated that the treatment is safe and feasible, but they have not shown significant regeneration of alveolar tissue or functional reversal of emphysema. The challenges are substantial: very few of the administered cells actually take up residence in the damaged lung, the diseased tissue creates a hostile environment for new cell growth, and researchers are still working out the basics of how many cells to deliver and by what route.
Meanwhile, laboratory work on decellularized lung scaffolds, essentially the structural skeleton of a donor lung stripped of its cells, has shown that stem cells can be coaxed to grow into lung-like tissue on these frameworks. This is far from a transplantable organ, but it represents a building block for future bioengineered lung tissue.
If you see a clinic advertising stem cell therapy for emphysema today, be skeptical. No stem cell treatment for COPD has been approved by major regulatory agencies, and the clinics offering it are running well ahead of the evidence.
Oxygen Therapy and When It Helps
As emphysema progresses, damaged lungs may no longer deliver enough oxygen to the blood, a condition called hypoxemia. For people with severe, resting hypoxemia, long-term supplemental oxygen has been shown to improve survival, reduce strain on the heart, and bring down abnormally high red blood cell counts that the body produces in response to chronic oxygen deprivation.
The picture is less clear for people with moderate oxygen drops, such as those whose levels dip only during exercise or sleep. A large randomized trial found no significant difference in time to death or first hospitalization between patients with moderate desaturation who used supplemental oxygen and those who did not. This was a surprising result that changed clinical practice: oxygen is not a blanket recommendation for everyone with COPD, but rather a targeted therapy for those with the most severe oxygen deficits.
Lung Transplantation as a Last Resort
For end-stage emphysema that does not respond adequately to other treatments, lung transplantation remains the only option that replaces the damaged organ entirely. The procedure can involve one lung or both, depending on the transplant center’s experience, donor availability, and the individual patient’s risk profile. Life expectancy and quality of life generally improve after transplantation, and outcomes tend to be somewhat better with a double transplant than a single one.
Transplantation, however, is not a simple fix. The immune system treats the new lung as foreign tissue, and up to half of recipients develop chronic lung allograft dysfunction within five years, a form of rejection that progressively damages the transplanted lung and is very difficult to treat effectively. Recipients also face elevated risk of certain cancers due to the immunosuppressive drugs they must take for life. These realities make transplantation a carefully weighed decision rather than a default next step.
Non-Smoking Causes and the Global Picture
While cigarette smoking dominates the conversation around emphysema in high-income countries, a significant share of COPD worldwide is driven by something else entirely: indoor exposure to biomass smoke from cooking and heating fuels like wood and coal. This is most common in lower-income countries where solid fuels are burned in poorly ventilated spaces, and women and children bear the greatest exposure. The connection between biomass smoke and COPD is well supported by population studies, though the precise biological mechanisms by which this smoke destroys lung tissue are still less well understood than those behind cigarette-related damage.
This distinction matters because the prevention strategy is completely different. Quitting smoking is personal; reducing biomass exposure requires cleaner cookstoves, improved ventilation, and access to alternative fuels, challenges that sit at the intersection of public health, energy policy, and economic development.
Muscle Wasting and the Body Beyond the Lungs
Emphysema is often thought of as purely a lung disease, but it takes a toll on the whole body. Somewhere between 15 and 40 percent of people with COPD experience significant muscle wasting, with the exact prevalence depending on how it is measured and how advanced the disease is. This loss of muscle is not just a side effect of being sedentary. It is an independent predictor of death in COPD, separate from how obstructed the airways are.
People with the emphysema-predominant form of COPD tend to lose more muscle mass in the trunk and torso than those with other subtypes. The reasons are complex, involving chronic inflammation, poor nutrition due to the sheer effort of breathing, and hormonal changes. This is one reason pulmonary rehabilitation programs emphasize strength training alongside aerobic exercise: preserving muscle mass is not cosmetic, it is survival-relevant.
Advanced Imaging and Earlier Detection
One reason emphysema is hard to catch early is that standard lung function tests only flag problems once a substantial amount of tissue is already gone. CT scans can detect emphysema visually, but newer imaging techniques are pushing the boundary further. Hyperpolarized xenon-129 MRI allows researchers to watch gas exchange happening in real time across different regions of the lung. In studies comparing COPD patients to healthy volunteers, this technique has been able to distinguish between different types of underlying pathology, even in patients whose standard diffusion tests look similar.
The practical promise is that imaging like this could eventually identify which regions of the lung are failing and why, guiding treatment decisions with much more precision than a single number from a breathing test. For someone considering endobronchial valve placement, for instance, detailed regional maps of gas exchange could help identify the optimal target lobe. For researchers testing regenerative therapies, it could provide a way to detect early signs of tissue repair that standard tests would miss.